During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety ...

The tissue damage and anatomical distortion caused by primary prostate cancer treatment are major challenges for surgeons performing salvage surgery.

Men with non-metastatic forms are likely to live 'for many years' after diagnosis when active surveillance and other NCCN ...

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Prostate cancer focal therapies include cryotherapy, irreversible electroporation ablation (IRE), & high-intensity focused ultrasound (HIFU).

Some of his research on prostate cancer -- which showed for the first time that targeted exercise decreases bone loss in men with prostate cancer who were on androgen deprivation therapy -- is ...

A breakthrough in prostate cancer treatment is now available in Cincinnati, and it changed one patient's life faster than he ...

Prostate cancer is the second most common cancer diagnosis in men. About one in eight men will be diagnosed with this disease during their lifetime. New Mexico Living spoke with Dr. Jose Avitia ...